Clinical trials: Attention Disorder With Hyperactivity (ADHD)
- Condition Attention Disorder With Hyperactivity (ADHD)
- Funder type Industry (pharma, biotech, devices)
Attention Deficit Hyperactivity Disorder
Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With ADHD
The purpose of this protocol is to investigate the acute treatment efficacy, safety, and tolerability of atomoxetine on a once-daily dosing strategy in Taiwanese children and adolescents with ADHD.
- Trial name
- NCT00485459
- Testing
- Atomoxetine Hydrochloride
- Where
- Taiwan
- Volunteers
- 106 people
- Sponsor
- Eli Lilly and Company
Healthy, CVA
Development of Automated Analysis to Electroencephelogram (EEG) Data in Patients Treated at the Sagol Hyperbaric Medicine and Research Center at the Years 2017-2019.
DELPhI software developed for the analysis of EEG recordings in response to magnetic stimulation in relation to clinical data.
- Conditions
- Healthy, CVA, Hemorrhage, TBI (Traumatic Brain Injury)
- Trial name
- NCT04095377
- Testing
- No intervention, this is a retrospective study.
- Where
- Israel
- Volunteers
- 875 people, healthy volunteers welcome
- Sponsor
- QuantalX Neuroscience
No History of ADHD, Attention Deficit Hyperactivity Disorder (ADHD)
An Investigational Study Examining the Cross-Validation of QbMobile in ADHD and Normative Populations
The purpose of this study is to investigate QbMobile ability to collect and provide accurate and objective data which can be used to facilitate assessment and treatment procedures for ADHD in a clinical setting as well as…
- Conditions
- No History of ADHD, Attention Deficit Hyperactivity Disorder (ADHD), Healthy Volunteer
- Trial name
- NCT07220330
- Testing
- QbMobile
- Where
- 3 sites in United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Qbtech AB
Attention Deficit Hyperactivity Disorder (ADHD), Binge-Eating Disorder Disorder
Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver Dysfunction
Study of the what the body does to the drug in subjects with mild, moderate, and sever liver dysfunction (not working properly)
- Trial name
- NCT02795637
- Testing
- dasotraline
- Where
- 5 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Sumitomo Pharma America, Inc.
Attention Deficit Disorder With Hyperactivity
Efficacy and Safety of SPD465 in Adults With ADHD
The purpose of this study is to assess the safety and effectiveness of SPD465 compared to placebo (a capsule with no medication in it) in the treatment of ADHD.
- Trial name
- NCT00150579
- Testing
- Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate
- Volunteers
- 240 people
- Sponsor
- Shire
Attention-Deficit Hyperactivity Disorder (ADHD)
PDC-1421 Treatment in Adult Patients With ADHD
Part II is a double-blind, randomized, parallel-group, placebo-controlled study. The primary objective of this trial is to determine the effective doses and treatment period of PDC-1421 Capsule in subjects with ADHD.
- Trial name
- NCT05202327
- Testing
- PDC-1421 Capsule
- Where
- 6 sites in United States, Taiwan
- Volunteers
- 99 people
- Sponsor
- BioLite, Inc.
Attention Deficit Hyperactivity Disorder, Dyslexia
Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia
This study will evaluate the effect of atomoxetine in treating Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in children and adolescents with ADHD and comorbid reading disability (dyslexia)
- Trial name
- NCT00607919
- Testing
- Atomoxetine
- Where
- 16 sites in United States
- Volunteers
- 209 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder (ADHD)
Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of SHP465 in children aged 4 to 5 years with ADHD after multiple daily doses of 6.25 milligram (mg) SHP465
- Trial name
- NCT03327402
- Testing
- SHP465
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Shire
Attention Deficit Disorder With Hyperactivity
A Trial to Characterize Differences in Blood Levels of Different Lots of Centanafadine QD XR and to Understand the Effect of Food on Blood Levels
The purpose of this study is to evaluate the dose strength equivalence of to-be-marketed (TBM) centanafadine (CTN) once daily (QD) extended release (XR) when administered as 2 capsules of 164.4 milligrams (mg) or as a single…
- Trial name
- NCT07253441
- Testing
- CTN XR (TBM), CTN SR, CTN XR (Clin)
- Where
- 2 sites in United States
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Hyperactivity Disorder
Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate
The purpose of the AR19.004 study is to assess the efficacy of AR19 compared to placebo using the Adult ADHD Investigator Symptom Rating Scale (AISRS)
- Trial name
- NCT03659929
- Testing
- Amphetamine Sulfate
- Where
- 31 sites in United States
- Volunteers
- 320 people
- Sponsor
- Arbor Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder
An Effectiveness and Safety Study of CONCERTA* vs. Immediate Release Methylphenidate (IR MPH) in Attention Deficit Hyperactivity Disorder Children
The purpose of this study is to determine the effectiveness and safety of OROS*methylphenidate/CONCERTA* vs. immediate release methylphenidate as a treatment for ADHD specifically for those children who have behavioural…
- Trial name
- NCT00304681
- Testing
- OROS*-Methylphenidate
- Volunteers
- 147 people
- Sponsor
- Janssen-Ortho Inc., Canada
Attention Deficit Hyperactivity Disorder, Substance Use Disorders
CBT for Patients With Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorders
The purpose of this study is to determine if cognitive behavioral therapy is effective in treating ADHD symptoms in patients with substance use disorders and comorbid ADHD.
- Trial name
- NCT01431235
- Testing
- cognitive behavioral therapy for treating ADHD symptoms
- Where
- Netherlands
- Volunteers
- 184 people
- Sponsor
- Arkin
Attention-deficit Hyperactivity Disorder (ADHD)
Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder
This trial is a Phase 1 study in adolescents with ADHD and genetic disruptions impacting genes in the metabotropic glutamate receptor (mGluR) network.
- Trial name
- NFC1-GREAT (NCT02286817)
- Testing
- NFC-1
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Adult Attention Deficit Hyperactivity Disorder
Adult Attention Deficit Hyperactivity Disorder
A Phase 2 study of SEP-225289 in adults with attention deficit hyperactivity disorder (ADHD).
- Trial name
- NCT01692782
- Testing
- SEP-225289
- Where
- 31 sites in United States
- Volunteers
- 341 people
- Sponsor
- Sumitomo Pharma America, Inc.
Attention Deficit Hyperactivity Disorder (ADHD)
Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients
The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in adult ADHD patients.
- Trial name
- NCT06931080
- Testing
- EB-1020 (Centanafadine) 164.4 mg, EB-1020 (Centanafadine) 328.8 mg
- Where
- Japan
- Volunteers
- 630 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Attention-Deficit/Hyperactivity Disorder
A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
The objective of this study is to evaluate the long-term safety and tolerability of ABT-089 in children with ADHD.
- Trial name
- NCT00554385
- Testing
- ABT-089
- Where
- 23 sites in United States
- Volunteers
- 283 people
- Sponsor
- Abbott
Attention Deficit/Hyperactivity Disorder
International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder
The aim of the iSPOT-A study is to: 1. identify brain, genetic and cognitive markers of Attention Deficit/Hyperactivity Disorder, and 2.
- Trial name
- NCT00863499
- Testing
- Short Acting Methylphenidate, Long Acting Methylphenidate
- Where
- 7 sites in United States, Australia and 1 more
- Volunteers
- 1,344 people, healthy volunteers welcome
- Sponsor
- BRC Operations Pty. Ltd.
Attention-Deficit/Hyperactivity Disorder
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.
- Trial name
- NCT04781140
- Testing
- 100mg SPN-812
- Where
- 54 sites in United States
- Volunteers
- 286 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder
Comparison Atomoxetine Hydrochloride and Comparator in Pediatric Outpatients With ADHD
The purpose of the study is to compare atomoxetine hydrochloride and methylphenidate hydrochloride in pediatric patients with ADHD.
- Trial name
- NCT00486083
- Testing
- Atomoxetine Hydrochloride, Methylphenidate Hydrochloride
- Where
- 3 sites in China, Mexico and 1 more
- Volunteers
- 330 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Phase 3 Randomized Double-Blind Placebo-Controlled Study of NRP104 in Children Aged 6-12 With ADHD
This study is designed to assess efficacy and safety of NRP-104 administered as a daily dose of 30mg, 50mg or 70mg compared to placebo in the treatment of children aged 6-12 years with ADHD.
- Trial name
- NCT00556296
- Testing
- NRP104
- Volunteers
- 297 people
- Sponsor
- New River Pharmaceuticals